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Part V
Clinical Applications of Psoralens,
and Related Materials
VITILIGO—WHAT IS IT?'
HERMANN PINKUS, M.D.
'When I first became interested in vitiligo in
connection with psoralen therapy, the answer to
the question: what is vitiligo? seemed to be very
simple. Every textbook gives a clear-cut defini-
tion.
DEFINITION
To quote Ormsby-Montgomery (1): "Vitiligo
is an acquired cutaneous achromia characterized
by variously sized and shaped single or multiple
patches of milk white color, usually presenting
hyperpigmented borders and a tendency to
enlarge peripherally." The authors add to this:
"Absence of pigment. . . is the only symptom in
vitiligo". . . . "The skin. . . presents no textural
changes and is normal in every way except a
sensitiveness to solar irradiation". . . "the cause
of vitiligo is unknown". . . "the treatment of the
disorder is unsatisfactory".
Other books offer similar definitions, all of
them almost completely negative, except for that
one positive fact: acquired loss of pigment with
a general progressive tendency.
The attribute "acquired" differentiates vitiligo
from partial albinism which is congenital. The
attribute "progressive" also sets it apart from
albinism in which the white areas do not enlarge,
and from leukodermas following injury, such as
superficial burns, or inflammatory dermatoses,
such as syphilis or psoriasis. These secondary
leukodermas generally are transient and decrease
rather than increase with time.
Now, several years later, after observing
numerous cases of vitiligo closely, following their
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course with and without therapy, and reading
whatever could be found in the literature, the
picture has become more diversified and even
more puzzling.
CLINICAL MORPhOLOGy
Concerning the clinical picture and course, it
is certainly true that most lesions show a com-
plete absence of pigment and a tendency to
progress. However, some patients report that
every summer, on exposure to sunshine, there is
some repigmentation from the borders, and small
pigmented, freckle-like spots may appear in the
center of white areas, only to disappear again
during the winter. The difference is a real one and
is not due to enhanced color contrast between
tanned and vitiliginous skin in the summer. Re-
pigmentation of some degree occurs in 50% of
patients according to Lerner (2).
Other patients exhibit what Siemens (3) re-
cently has called "vitiligo gradata", a graded,
step-wise diminution of pigment. This feature is
especially noticeable in colored skin, but may be
observed in whites. Between the normal and the
totally depigmented skin, there are zones of
varying width exhibiting an intermediate hue.
The borders always are sharp, not shading grad-
ually. The German term "Stufen-Vitiligo"
(vitiligo by steps) expresses this phenomenon.
While Siemens describes this as a secondary
development due to partial repigmentation, I
have seen it also in progressing lesions as a step-
wise depigmentation.
Another peculiar experience is that patients
under treatment with methoxsalen may show
repigmentation of the majority of areas, while
others may progress. New areas even may appear.
The hyperpigmented border, mentioned by
niany authors, has been explained as an optical
illusion by others. We will see later that there is
histologic evidence that hyperpigmentation is
indeed present. It is often quite prominent when
repigmentation occurs under therapy.
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Another point worth mentioning is the behav-
ior of hair color. In some vitiliginous patches, the
hairs retain their natural color, even in large
areas of long standing. In other cases, the hairs
become white sooner or later. In this connection,
it has been a general experience that the freckle-
like pigment spots, which appear within vitiligi-
nous areas spontaneously or under therapy,
almost always are perifollicular and seem to
occur only where the hairs have preserved their
color. It is quite rare for new centers of pigment
to appear on the non-hairy surfaces. Prognosis for
repigmentation is better if the color of the hair is
preserved because each hair may then serve as a
center from which pigmentation spreads. On the
other hand, the epidermis of relatively small
areas may become repigmented from the borders
even though the hairs remain white. In rare cases,
white hairs may turn dark again under treat-
ment.
The pigmentary systems of epidermis and hairs
thus seem to be under independent control.
Similarly lijima and Kanazawa (4) observed
that a blue nevus did not depigment and retained
a positive dopa reaction when the epidennis above
it become vitiliginous. Another peculiar observa-
tion is the "halo nevus" or lcucoderma acquisitum
centrifugum (Sutton (5)). Here a brown mole
becomes surrounded by a depigmented halo that
has all the earmarks of vitiligo and may be asso-
ciated with other vitiliginous patches in the same
patient. It happens not infrequently that even-
tually the central nevus also becomes depig-
mented. It may even disappear completely,
being destroyed or absorbed by inflammatory
infiltrate.
ASSOCIATED LOCAL CHANGES
The statement that absence of melanin is the
only symptom in vitiligo has been challenged
repeatedly. Even Ormsby-Montgomery write
that histologic evidence of mild inflammation is
found in the border of the lesions. Cases have
been reported in which there was a narrow in-
flamed edge around the enlarging areas of
vitiligo (Habermanu (6)).
Habermann (6) writing in Jadassohn's Hand-
buch in 1933 quotes a variety of contradictory
observations that the vitiliginous skin is either
more or less susceptible to irritants such as
croton oil or mustard, and shows hyperreactivity
or hyporcactivity when tested with old tuber-
culin, diphtheria toxin and other allergens.
Diminution of spontaneous sweating and of
sweat response to pilocarpin has been reported
by several authors, but has been denied by others
(7). Among recent authors, Halter (8) found
heat sweating absent in vitiliginous skin although
response to pilocarpin was not disturbed. Lerncr
(9) reports that under resting conditions, more
sweat occurs in areas of vitiligo than on adjacent
normal skin and that the electrical resistance is
decreased in the vitiliginous areas (2). Lerner
(9) also quotes reports that blood vessels are
constricted in patches of vitiligo and that viti-
liginous skin does not become yellow during
jaundice or on ingestion of atabrine. Hypesthesia
has been claimed occasionally to occur in cases
in which leprosy could be ruled out. Habermann
wonders whether such cases may not have been
incipient tabes dorsalis in which according to
him, vitiligo is found not infrequently.
ASSOCIATION WITH SYSTEMIC DI5EASE
This brings up the much discussed question of
systemic diseases associated with and perhaps
causative of vitiligo. Habermann listed the fol-
lowing:
T7itiligo and Systemic Disease
A. Diseases of the Nervous System
a. psychic disturbances and neuroses
b. disorders of sensory or motor nerves
c. disorders of the vegetative nervous
system
B. Endocrine Disorders
a. thyroid (hyper- or hypo-)
b. adrenals
c. ovaries
d. others (parathyroid, thymus, pit-
uitary)
C. Infectious Diseases
a. syphilis
b. tuberculosis
c. others (typhoid, scarlet fever, etc.)
D. Other Systemic Diseases
a. pernicious anemia
b. alcoholism
c. liver, kidney, gastro-intestinal
Most of these reports arc based on few or even
individual cases in which the association certainly
could have been coincidental. Among the few
correlations that seem to be more valid, is that
with thyroid dysfunction, especially with thyro-
toxicosis in which figures as high as ten per cent
have been reported (Habermann). Allison and
Curtis (10) found an association of pernicious
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anemia and vitiligo in 22 eases out of 801,670
hospital admissions. Chance would have ac-
counted for only one case of this combination.
Lerner (2) found a tendency to hypochlorhydria
in a study of 25 patients. Excretion of norad-
renaline and melanocyte stimulating hormone
was normal in the same group of patients. So
were liver and thyroid function tests. Agarwala
et at. (11) found 17-ketosteroid excretion in-
creased.
The relationship of vitiligo to syphilis de-
serves a few comments. It is well known that
secondary syphilis may give rise to a character-
istic and long lasting leukoderma, which should
not be confused with true vitiligo. Tabes dorsalis,
formerly of very widespread occurrence, was
implicated because it is a nervous disorder, and
the influence of the nervous system on pigmenta-
tion has been discussed by many and for a long
time. Lerner (2) recently proposed the hypothesis
that vitiligo may result from increased activity
of the sympathetic nerves in the skin. It seems
that the causative role of syphilis had proponents
especially in France. Habermann wrote that in
France, even in 1933, most cases of vitiligo were
subjected to thorough antisyphilitic treatment
(pg. 933).
HJ5T0PATH0L0GJc CHANGES
In this confusion of opinions it is tempting to
turn to histopathologic examination for some
solid ground. Unfortunately, histologic data are
not too numerous. Many of the older ones must
be discounted because in a disease affecting the
pigment forming mechanism of the skin, exact
knowledge of that mechanism under normal con-
ditions is essential for correct interpretation of
its pathology. It has not been too many years
that the melanoeyte has been recognized as the
sole pigment forming cell and its extra-epidermal
derivation acknowledged by the great majority
of investigators. Becker, Jr. et at. (12) have
demonstrated the presence of junctional cells,
corresponding to melanocytes, but lacking the
ability of forming pigment, in sections of vitiligo.
They used gold impregnation for this purpose.
These "clear cells" or "white melanocytes" can
be seen at the dermo-epidermal junction in H and
E sections. All that is lacking is enzyme activity
when the sections are treated with dopa or
tyrosine, and of course there are no melanin
granules in melanocytes or epidermal cells. On
the other hand, one often sees unusually large,
highly dendritie, and highly melanized cells at
the border of the vitiliginous area. Here, one also
finds melanin-carrying macrophages in the cutis,
and often there is more or less inflammatory in-
filtrate around blood vessels of the upper corium.
These changes probably are responsible for the
clinical impression of a hyperpigmented areola.
Pathological changes of myelinated and non-
myelinated nerve fibers have been claimed by
some old and recent investigators, but these
findings need confirmation. Histamin (Quiroga
ci at. (13)) and sulfhydryl groups (Lajmanovich
and Magnin (14)) have been reported present in
normal quantity.
DISCUSSION
Vitiligo seems to be an achromia of the skin,
due not to any marked anatomical disturbance,
but purely to a functional abnormality of the
melanocytes. If the literature offers any hint to
an underlying systemic disturbance, this may be
in the neuro-endocrine field. Familial incidence is
common (Lerner (2)).
There have been several attempts to elucidate
the seat of the disturbance in the skin by ex-
change transplantation between normal and
vitiliginous areas. Results have been somewhat
contradictory. Haxthausen (quoted by Tolmach
(15)) found that split skin grafts changed color
quickly. Comel's (16) pedicle grafts preserved
their original color for several months, then
assumed the character of the surrounding skin.
Spencer (17) and Spencer and Tolmach (18)
found that full thickness grafts preserved their
original characteristics for as long as 16 months.
Kato (19) confirmed this difference in the behav-
ior of thin and thick grafts. There is, however, in
the work of Gillman et at. (20) some indication
that the epidermis of split skin grafts may be re-
placed by hair sheath cells of the host site even
after the graft seemingly has taken successfully.
This line of experimentation thus has not been
too helpful. If anything, the results seem to argue
against any immediate neural control of pig-
mentation.
There are a few clinical peculiarities which
make one wonder what the actual mechanism of
melanocyte inhibition is. In most cases, there is
an all-or-nothing effect. Not only clinically, even
under the microscope, the transition from normal
to abnormal skin is abrupt. Also, if repigmenta-
tion takes place spontaneously or under therapy,
it does not come in the form of gradual darkening
of the entire area, but by creeping extension of
pigment from the borders or from perifollicular
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foci. As the latter form oniy where the hair is
pigmented, it seems a fair assumption that
melanoeytes in the hair bulb serve as a source of
new pigment.
Theoretically, two mechanisms seem plausible
at the cellular level. Either, there is in vitiligo
a heritable change of melanocytes in certain foci,
and these abnormal achromatic melanocytes
multiply and push back the normal ones. In
repigmentation the tide of battle turns and the
abnormal cells are crowded out. Or, the cells
stay where they are and there is an "infectious"
spread of inhibition of pigment formation from
cell to cell. Inhibition may result from some kind
of blockage of the enzyme or from actual loss
of the enzyme forming mechanism. Repigmenta-
tion then would take place by a similar "in-
fectious" spread of either the enzyme mechanism
or an "unblocking" agent. Examples for either
cell migration or infectious spread of pigment
forming ability are present in experimental work
in animals.
In any case, the therapeutic action of the
psoralens in vitiligo seems to require the presence
of four cooperating factors: The drug, photo-
chemical energy, the presence of achromatic
"diseased" melanocytes, and last but not least,
the presence of normal melanocytes in contact
with the diseased ones. It seems open to argu-
ment whether the drug and ultraviolet exert
their influence on the diseased cell, or perhaps
rather on the normal one, if not both (Fig. 1).
SUMMARY
(1) Vitiligo is an acquired progressive aehro-
mia due to loss of function of the tyrosinase sys-
tem of the melanocytes at the epidermo-dermal
junction.
(2) Clinical peculiarities and systemic asso-
ciations of vitiligo are reviewed.
(3) The importance of the presence of func-
tional melanocytes in contact with the diseased
ones is emphasized in the explanation of spon-
taneous and therapeutic repigmentation, and the
question is raised whether the psoralens exert
their action on the normal melanocyte rather
than on the diseased one.
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